Loading...
Ceritinib enhances the efficacy of trametinib in BRAF/NRAS-wild type melanoma cell lines
Targeted therapy options are currently lacking for the heterogeneous population of patients whose melanomas lack BRAF or NRAS mutations (~35% of cases). We undertook a chemical biology screen to identify potential novel drug targets for this understudied group of tumors. Screening a panel of 8 BRAF/...
Na minha lista:
| Udgivet i: | Mol Cancer Ther |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5752595/ https://ncbi.nlm.nih.gov/pubmed/29133622 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0196 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|